Skip to main content

Table 4 Multivariate analysis by Cox proportional hazards regression model and diagnostic accuracy of 180-day mortality

From: Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study

Markers 180-day mortality
  HRa 95 % CI p Sensitivity 95 % CI Specificity 95 % CI ROC-AUC 95 % CI p
PTX3 1.05 0.47–2.35 0.902 0.69 0.53–0.82 0.56 0.50–0.60 0.66 0.56–0.76 0.005
PTX3b 1.34 0.60–3.00 0.480 0.67 0.51–0.80 0.68 0.62–0.72 . . .
PCT 0.86 0.38–1.95 0.713 0.66 0.50–0.79 0.55 0.49–0.60 0.65 0.55–0.76 0.007
CRP 0.71 0.34–1.51 0.376 0.34 0.21–0.50 0.41 0.36–0.47 0.32 0.21–0.43 0.001
PTX3 + PCT . . . . . . . 0.66 0.56–0.76 0.005
PTX3 + CRP . . . . . . . 0.72 0.61–0.82 <0.0001
PCT + CRP . . . . . . . 0.71 0.60–0.82 <0.0001
PTX3 + PCT + CRP . . . . . . . 0.72 0.62–0.83 <0.0001
  1. Hazard ratio, sensitivity and specificity are calculated for high (above median) versus low (below median) baseline levels of the inflammatory biomarkers. Five patients are not included in the analysis due to missing data regarding Simplified Acute Physiology Score II
  2. aAdjusted for age, sex, Simplified Acute Physiology Score II and chronic disease (yes/no)
  3. bPTX3 dichotomized by the optimal cutoff (69.8 ng/ml) found by the ROC curve (highest sum of sensitivity and specificity)
  4. CRP C-reactive protein, HR Hazard ratio, PCT Procalcitonin, PTX3 Pentraxin-3, ROC-AUC Receiver operating characteristic-area under the curve, CI Confidence interval
  5. Dots: Values cannot be given